Literature DB >> 15703161

Clarithromycin-nifedipine interaction as possible cause of vasodilatory shock.

Manuel Gerónimo-Pardo1, Ana B Cuartero-del-Pozo, José M Jiménez-Vizuete, Manuel Cortiñas-Sáez, Ramón Peyró-García.   

Abstract

OBJECTIVE: To report a case of vasodilatory shock possibly resulting from a clarithromycin-nifedipine interaction. CASE
SUMMARY: A 77-year-old male with uncontrollable hypertension developed shock, heart block, and multiorgan failure 2 days after clarithromycin was added to his antihypertensive treatment (nifedipine, captopril, doxazosin). Invasive monitoring revealed hyperdynamic shock with decreased systemic vascular resistances. DISCUSSION: Nifedipine is metabolized by isoenzyme CYP3A4. This metabolic pathway is inhibited by clarithromycin, thus potentially increasing the plasma nifedipine concentration, which may lead to excessive calcium-channel blocker effects. Clinical manifestations of excessive calcium-channel blockade comprise hypotension or vasodilatory shock and heart block, as in our case. An objective causality assessment revealed that this drug interaction was the possible cause of these adverse effects. Because of an initial diagnosis of septic shock, suspicion of this entity was delayed and specific diagnostic and treatment were not possible.
CONCLUSIONS: This life-threatening clinical picture, including shock and heart block, was possibly the result of a pharmacokinetic interaction between clarithromycin and nifedipine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703161     DOI: 10.1345/aph.1E432

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  6 in total

Review 1.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

2.  The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers.

Authors:  Alissa J Wright; Tara Gomes; Muhammad M Mamdani; John R Horn; David N Juurlink
Journal:  CMAJ       Date:  2011-01-17       Impact factor: 8.262

3.  Drug utilization of clarithromycin for gastrointestinal disease treatment.

Authors:  Quan Zhou; Ling-Ling Zhu; Xiao-Feng Yan; Wen-Sheng Pan; Su Zeng
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

4.  Drug-drug interactions and acute kidney injury: caveat prescriptor.

Authors:  Mallika L Mendu; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2014-05-10       Impact factor: 8.860

5.  Interaction between midazolam and clarithromycin in the elderly.

Authors:  Sara K Quinney; Barbara D Haehner; Melissa B Rhoades; Zhen Lin; J Christopher Gorski; Stephen D Hall
Journal:  Br J Clin Pharmacol       Date:  2007-07-17       Impact factor: 4.335

6.  Hypotension induced by the concomitant use of a calcium-channel blocker and clarithromycin.

Authors:  Sayako Takeuchi; Yuki Kotani; Toshihide Tsujimoto
Journal:  BMJ Case Rep       Date:  2017-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.